Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0F6GX
|
|||
Former ID |
DNC006334
|
|||
Drug Name |
Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3
|
|||
Synonyms |
CHEMBL202699; Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3; BDBM50179459; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C40H48N8O6
|
|||
Canonical SMILES |
CC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NC
|
|||
InChI |
1S/C40H48N8O6/c1-25(49)45-34(23-27-15-18-31(50)19-16-27)38(53)48-35(22-26-9-4-3-5-10-26)39(54)46-32(13-8-20-44-40(41)42)37(52)47-33(36(51)43-2)24-28-14-17-29-11-6-7-12-30(29)21-28/h3-7,9-12,14-19,21,32-35,50H,8,13,20,22-24H2,1-2H3,(H,43,51)(H,45,49)(H,46,54)(H,47,52)(H,48,53)(H4,41,42,44)/t32-,33-,34-,35+/m0/s1
|
|||
InChIKey |
QVTMGASDQFBYLJ-AYXCPNKJSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Melanocortin receptor 1 (MC1R) | Target Info | Inhibitor | [1] |
Melanocortin receptor 3 (MC3R) | Target Info | Inhibitor | [1] | |
Melanocortin receptor 4 (MC4R) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Melanogenesis | ||||
Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.